MCL-1 inhibition in cancer treatment

被引：111

作者：

Xiang, Weiguo ^{[1
]}

Yang, Chao-Yie ^{[1
,2
]}

Bai, Longchuan ^{[1
,2
]}

机构：

[1] Univ Michigan, Dept Internal Med, Med Sch, Ann Arbor, MI 48109 USA

[2] Univ Michigan, Rogel Canc Ctr, 1600 Huron Pkwy,Bldg 520-G352, Ann Arbor, MI 48109 USA

来源：

ONCOTARGETS AND THERAPY | 2018年 / 11卷

关键词：

BCL-2; BAX; BAK; apoptosis; BH3; mimetics; SMALL-MOLECULE INHIBITOR; TARGETING MCL-1; DOWN-REGULATION; GAMBOGIC ACID; DIFFERENTIAL REGULATION; BH3-ONLY PROTEINS; COPY-NUMBER; IN-VITRO; BCL-2; APOPTOSIS;

D O I：

10.2147/OTT.S146228

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Myeloid cell leukemia-1 (MCL-1), a member of antiapoptotic BCL-2 family proteins, is a key regulator of mitochondrial homeostasis. Frequent overexpression of MCL-1 in human primary and drug-resistant cancer cells makes it an attractive cancer therapeutic target. Significant progress has been made in the development of small-molecule MCL-1 inhibitors in recent years, and three MCL-1 selective inhibitors have advanced to clinical trials. This review briefly discusses recent advances in the development of small molecules targeting MCL-1 for cancer therapy.

引用

页码：7301 / 7314

页数：14

共 50 条

[1] Modelling MCL-1 inhibition in breast cancer
Campbell, Kirsteen
Dhayade, Sandeep
Ferrari, Nicola
Johnson, Emma
Hair, Jane
Edwards, Joanne
Tait, Stephen
Blyth, Karen
BREAST CANCER RESEARCH AND TREATMENT, 2016, 159 (01) : 185 - 185
[2] Small molecule Mcl-1 inhibitors for the treatment of cancer
Belmar, Johannes
Fesik, Stephen W.
PHARMACOLOGY & THERAPEUTICS, 2015, 145 : 76 - 84
[3] Allosteric inhibition of antiapoptotic MCL-1
Susan Lee
Thomas E Wales
Silvia Escudero
Daniel T Cohen
James Luccarelli
Catherine G Gallagher
Nicole A Cohen
Annissa J Huhn
Gregory H Bird
John R Engen
Loren D Walensky
Nature Structural & Molecular Biology, 2016, 23 : 600 - 607
[4] Allosteric inhibition of antiapoptotic MCL-1
Lee, Susan
Wales, Thomas E.
Escudero, Silvia
Cohen, Daniel T.
Luccarelli, James
Gallagher, Catherine G.
Cohen, Nicole A.
Huhn, Annissa J.
Bird, Gregory H.
Engen, John R.
Walensky, Loren D.
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2016, 23 (06) : 600 - 607
[5] MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment
Alcon, Clara
Martin, Fernando
Prada, Estela
Mora, Jaume
Soriano, Aroa
Guillen, Gabriela
Gallego, Soledad
Roma, Josep
Samitier, Josep
Villanueva, Alberto
Montero, Joan
CELL DEATH DISCOVERY, 2022, 8 (01)
[6] MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment
Clara Alcon
Fernando Martín
Estela Prada
Jaume Mora
Aroa Soriano
Gabriela Guillén
Soledad Gallego
Josep Roma
Josep Samitier
Alberto Villanueva
Joan Montero
Cell Death Discovery, 8
[7] Mcl-1 inhibition as a novel approach for personalized breast cancer therapy
Bashari, M. H.
Malvestiti, S.
Fan, F.
Vallet, S.
Sattler, M.
Cardone, M. H.
Opferman, J. T.
Jaeger, D.
Podar, K.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 117 - 117
[8] BRAF/MEK inhibitors selectively prime melanoma for Mcl-1 dependence and sensitize to Mcl-1 inhibition
Kump, Karson J.
Miao, Lei
Ansari, Nurul
Lombard, David B.
Nikolovska-Coleska, Zaneta
CANCER RESEARCH, 2019, 79 (13)
[9] Targeting Mcl-1 for the therapy of cancer
Quinn, Bridget A.
Dash, Rupesh
Azab, Belal
Sarkar, Siddik
Das, Swadesh K.
Kumar, Sachin
Oyesanya, Regina A.
Dasgupta, Santanu
Dent, Paul
Grant, Steven
Rahmani, Mohamed
Curiel, David T.
Dmitriev, Igor
Hedvat, Michael
Wei, Jun
Wu, Bainan
Stebbins, John L.
Reed, John C.
Pellecchia, Maurizio
Sarkar, Devanand
Fisher, Paul B.
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (10) : 1397 - 1411
[10] Individualized breast cancer therapy using Mcl-1 inhibition based combination
Bashari, M. H.
Malvestiti, S.
Fan, F.
Vallet, S.
Cardone, M. H.
Opferman, J. T.
Jaeger, D.
Podar, K.
ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →